Dokumendiregister | Terviseamet |
Viit | 11.2-1/24/12870-3 |
Registreeritud | 17.12.2024 |
Sünkroonitud | 18.12.2024 |
Liik | Sissetulev dokument |
Funktsioon | 11.2 Turustamise eelne järelevalve (pre-marketing surveillance) |
Sari | 11.2-1 Meditsiiniseadmete kliiniliste uuringute ja toimivusuuringute dokumendid (taotlused, load, muud teavitused ja kirjavahetus) |
Toimik | 11.2-1/2024 |
Juurdepääsupiirang | Avalik |
Juurdepääsupiirang | |
Adressaat | IQVIA MedTech |
Saabumis/saatmisviis | IQVIA MedTech |
Vastutaja | Merili Saar-Abroi (TA, Peadirektori asetäitja (1) vastutusvaldkond, Meditsiiniseadmete osakond) |
Originaal | Ava uues aknas |
From: "Podolak, Amira" <[email protected]>
Sent: Thu, 05 Dec 2024 08:57:07 +0000
To: "Meditsiiniseadmed (Medical Devices)" <[email protected]>
Subject: RE: Change of competent authority for medical devices studies
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. |
Dear Ms Merili Saar-Abroi,
May I have one more question? I’d like to check how this transfer eventually impact the payment process. Are we still supposed to write an email with an invoice request and then proceed with paying the CA fee and state fee (separately) just using new CA’s details? I’d appreciate your confirmation.
Kind regards,
Amira Podolak, Ph.D.
Associate Regulatory & Start-Up Manager
IQVIA MedTech, Clinical Operations
Learn more about IQVIA MedTech
Home Based (Gdynia, Poland)
tel. +48 22 430 31 34
Upcoming ooo: 23-24Dec (holidays), 25-26Dec (BH), 27-31Dec (holidays), 01Jan (BH)
From: Meditsiiniseadmed (Medical Devices) <[email protected]>
Sent: Tuesday, December 3, 2024 8:40 AM
To: Podolak, Amira <[email protected]>
Cc: Farinha, Ana <[email protected]>
Subject: Vs: Change of competent authority for medical devices studies
Dear Dr. Podolak,
Yes, all the procedures remain the same and are not affected by our transfer to State Agency of Medicines.
All the best,
Merili Saar-Abroi
Chief Specialist
Department of Medical Devices
Phone +372 554 3041
[email protected] | [email protected]
|
Terviseamet | Health Board +372 794 3500 [email protected]
Paldiski mnt 81, 10614 Tallinn |
This e-mail is confidential and meant for use by the person named in the letterhead. Any use in any way or copying of it by a person not marked as the addressee thereof is prohibited. If you have got this e-mail by mistake, please notify of it the sender without delay and delete the received e-mail together with all its attachments.
Saatja: Podolak, Amira <[email protected]>
Saatmisaeg: teisipäev, 3. detsember 2024 09:20
Adressaat: Meditsiiniseadmed (Medical Devices) <[email protected]>
Koopia: Farinha, Ana <[email protected]>
Teema: RE: Change of competent authority for medical devices studies
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. |
Dear Ms Merili Saar-Abroi,
Thank you very much for your prompt response and this explanation. I understand that both requirements and timelines remain the same after this transfer, correct? I would highly appreciate your confirmation.
Kind regards,
Amira Podolak, Ph.D.
Associate Regulatory & Start-Up Manager
IQVIA MedTech, Clinical Operations
Learn more about IQVIA MedTech
Home Based (Gdynia, Poland)
tel. +48 22 430 31 34
Upcoming ooo: 23-24Dec (holidays), 25-26Dec (BH), 27-31Dec (holidays), 01Jan (BH)
From: Meditsiiniseadmed (Medical Devices) <[email protected]>
Sent: Tuesday, December 3, 2024 7:41 AM
To: Podolak, Amira <[email protected]>
Cc: Farinha, Ana <[email protected]>
Subject: Vs: Change of competent authority for medical devices studies
Dear Dr. Podolak
According to the IVDR article 66, we are required to notify the sponsor as to whether the performance study falls within the scope of the IVDR and as to whether the application dossier is complete within 10 days of receiving the application. In case you apply December 17th at the latest, we will validate the application or ask for additional comments regarding your application December 27th at the latest. In 2025, we will be available again starting from January 6th. As we are transferring to the State Agency of Medicines starting from January 1st, 2025, our e-mail address from then on will be [email protected]
All of the medical devices department and it’s employees will be transferred from the Health Board to the State Agency of Medicines in full, therefore, the application will be transferred to the State Agency of Medicine automatically. No adjustments from the sponsor regarding our transfer are foreseen.
All fees remain valid and will be transferred internally from the Health Board and the State Agency of Medicines. The sponsor will not have any obligations regarding the fees already paid.
All the best,
Merili Saar-Abroi
peaspetsialist
meditsiiniseadmete osakond
+372 554 3041
[email protected] | [email protected]
|
Terviseamet +372 794 3500 [email protected]
Paldiski mnt 81, 10614 Tallinn |
Käesolev kiri on konfidentsiaalne ning mõeldud kasutamiseks kirja päises nimetatud isikule/asutusele. Käesoleva kirja mistahes viisil kasutamine või kopeerimine isiku poolt, kes ei ole märgitud selle adressaadiks, on keelatud. Kui te olete saanud käesoleva kirja ekslikult, palume sellest koheselt teavitada kirja saatjat ning kustutada saadud kiri koos kõikide lisadega.
Saatja: Podolak, Amira <[email protected]>
Saatmisaeg: esmaspäev, 2. detsember 2024 11:07
Adressaat: Meditsiiniseadmed (Medical Devices) <[email protected]>
Koopia: Farinha, Ana <[email protected]>
Teema: Change of competent authority for medical devices studies
Dear Sirs,
I would like to ask if there is any break planned for the Christmas period. If we apply before Christmas, is it likely that we will receive validation comments by the end of this year?
In addition, I would like to make sure how the evaluation of applications will look like due to the change in the authority for medical device testing? Will applications submitted in December still be evaluated by the Health Board, or will they be transferred to the State Agency of Medicines with the new year?
I would also like to ask if we do not manage to submit the application in December and have to submit it to the State Agency of Medicines in January, does the fee we have already submitted remain valid? Would we have to start some kind of procedure to redirect the funds or refund and make the payment again to the new competent authority?
I would highly appreciate your feedback on these matters.
Kind regards,
Amira Podolak, Ph.D.
Associate Regulatory & Start-Up Manager
IQVIA MedTech, Clinical Operations
Learn more about IQVIA MedTech
Home Based (Gdynia, Poland)
tel. +48 22 430 31 34
Upcoming ooo: 23-24Dec (holidays), 25-26Dec (BH), 27-31Dec (holidays), 01Jan (BH)
________________________________________
IMPORTANT - PLEASE READ: This electronic message, including its attachments, is CONFIDENTIAL and may contain PROPRIETARY
or LEGALLY PRIVILEGED or PROTECTED information and is intended for the authorized recipient of the sender. If you are not the intended recipient, you are hereby notified that any use, disclosure, copying, or distribution of this message or any of the information
included in it is unauthorized and strictly prohibited. If you have received this message in error, please immediately notify the sender by reply e-mail and permanently delete this message and its attachments, along with any copies thereof, from all locations
received (e.g., computer, mobile device, etc.). To the extent permitted by law, we may monitor electronic communications for the purposes of ensuring compliance with our legal and regulatory obligations and internal policies. We may also collect email traffic
headers for analyzing patterns of network traffic and managing client relationships. For further information see our
privacy-policy. Thank you.
Nimi | K.p. | Δ | Viit | Tüüp | Org | Osapooled |
---|---|---|---|---|---|---|
Kiri | 17.12.2024 | 1 | 11.2-1/24/12870-1 | Sissetulev dokument | ta | IQVIA MedTech |
Vastuskiri | 17.12.2024 | 1 | 11.2-1/24/12870-4 | Väljaminev dokument | ta | IQVIA MedTech |
Vastuskiri | 17.12.2024 | 1 | 11.2-1/24/12870-2 | Väljaminev dokument | ta | IQVIA MedTech |